VENUS MEDTECH (HANGZHOU) INCVENUS MEDTECH (HANGZHOU) INCVENUS MEDTECH (HANGZHOU) INC

VENUS MEDTECH (HANGZHOU) INC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.48 B‬HKD
−1.38HKD
‪−777.65 M‬HKD
‪542.97 M‬HKD
‪288.09 M‬
Beta (1Y)
−2.04
Employees (FY)
865
Change (1Y)
−163 −15.86%
Revenue / Employee (1Y)
‪627.71 K‬HKD
Net income / Employee (1Y)
‪−899.01 K‬HKD

About VENUS MEDTECH (HANGZHOU) INC


CEO
Hou-Sen Lim
Headquarters
Wanchai
Founded
2009
ISIN
CNE100003PJ8
FIGI
BBG00QTMSFW3
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 2500 is 5.62 HKD — it has decreased by −0.71% in the past 24 hours. Watch VENUS MEDTECH (HANGZHOU) INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange VENUS MEDTECH (HANGZHOU) INC stocks are traded under the ticker 2500.
2500 reached its all-time high on Oct 12, 2020 with the price of 97.00 HKD, and its all-time low was 3.74 HKD and was reached on Oct 26, 2023. View more price dynamics on 2500 chart.
See other stocks reaching their highest and lowest prices.
2500 stock is 8.00% volatile and has beta coefficient of −2.04. Track VENUS MEDTECH (HANGZHOU) INC stock price on the chart and check out the list of the most volatile stocks — is VENUS MEDTECH (HANGZHOU) INC there?
Today VENUS MEDTECH (HANGZHOU) INC has the market capitalization of ‪2.46 B‬, it has increased by 4.24% over the last week.
Yes, you can track VENUS MEDTECH (HANGZHOU) INC financials in yearly and quarterly reports right on TradingView.
VENUS MEDTECH (HANGZHOU) INC is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
2500 earnings for the last half-year are −0.50 HKD per share, whereas the estimation was −0.44 HKD, resulting in a −14.63% surprise. The estimated earnings for the next half-year are −0.64 HKD per share. See more details about VENUS MEDTECH (HANGZHOU) INC earnings.
VENUS MEDTECH (HANGZHOU) INC revenue for the last half-year amounts to ‪247.89 M‬ HKD, despite the estimated figure of ‪274.36 M‬ HKD. In the next half-year revenue is expected to reach ‪332.49 M‬ HKD.
2500 net income for the last half-year is ‪−223.75 M‬ HKD, while the previous report showed ‪−381.97 M‬ HKD of net income which accounts for 41.42% change. Track more VENUS MEDTECH (HANGZHOU) INC financial stats to get the full picture.
No, 2500 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2024, the company has 865.00 employees. See our rating of the largest employees — is VENUS MEDTECH (HANGZHOU) INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VENUS MEDTECH (HANGZHOU) INC EBITDA is ‪−385.35 M‬ HKD, and current EBITDA margin is −94.22%. See more stats in VENUS MEDTECH (HANGZHOU) INC financial statements.
Like other stocks, 2500 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VENUS MEDTECH (HANGZHOU) INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VENUS MEDTECH (HANGZHOU) INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VENUS MEDTECH (HANGZHOU) INC stock shows the neutral signal. See more of VENUS MEDTECH (HANGZHOU) INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.